Paraoxonase and arylesterase levels in rheumatoid arthritis

Clinical Rheumatology

Volumn 26, Issue 3, 2007, Pages 342-348

  Isik, A ^a   Koca, S S ^a   Ustundag, B ^a   Celik, H ^b   Yildirim, A ^a  

^a FIRAT UNIVERSITY   (Turkey)

^b HARRAN UNIVERSITY   (Turkey)

Author keywords

Arylesterase; Lipid hydroperoxide; Paraoxonase; Rheumatoid arthritis

Indexed keywords

ARYLDIALKYLPHOSPHATASE; ARYLESTERASE; CERULOPLASMIN; LIPID HYDROPEROXIDE; THIOL GROUP;

ADULT; ANTIOXIDANT ACTIVITY; ARTICLE; ATHEROSCLEROSIS; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION COEFFICIENT; ENZYME ACTIVITY; FEMALE; HUMAN; MALE; OXIDATIVE STRESS; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; STUDENT T TEST; TISSUE INJURY;

ADULT; ARTHRITIS, RHEUMATOID; ARYLDIALKYLPHOSPHATASE; CARBOXYLIC ESTER HYDROLASES; CASE-CONTROL STUDIES; CERULOPLASMIN; FEMALE; HUMANS; LIPID PEROXIDATION; LIPID PEROXIDES; MALE; MIDDLE AGED; OXIDATIVE STRESS;

EID: 33947628713     PISSN: 07703198     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10067-006-0300-8     Document Type: Article

References (46)

1. Fox DA (2005) Etiology and pathogenesis of rheumatoid arthritis. In: Koopman WJ, Moreland LW (eds) Arthritis and allied conditions: A textbook of rheumatology, 15th edn. Lippincot Williams and Wilkins, Philadelphia, pp 1089-1115
2. Jasin HE (2005) Mechanisms of tissue damage in rheumatoid arthritis. In: Koopman WJ, Moreland LW (eds) Arthritis and allied conditions: A textbook of rheumatology, 15th edn. Lippincot Williams and Wilkins, Philadelphia, pp 1141-1164
3. Griffiths HR, Lunec J (1996) The C1q binding activity of IgG is modified in vitro by reactive oxygen species: Implications for rheumatoid arthritis. FEBS Lett 388(2-3):161-164
4. Nurcombe HL, Bucknall RC, Edwards SW (1991) Activation of the neutrophil myeloperoxidase-H2O2 system by synovial fluid isolated from patients with rheumatoid arthritis. Ann Rheum Dis 50(4):237-242
5. Sattar N, McCarey DW, Capell H, McInnes IB (2003) Explaining how "high-grade" systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 108(24):2957-2963
6. Zwerina J, Redlich K, Schett G, Smolen JS (2005) Pathogenesis of rheumatoid arthritis: Targeting cytokines. Ann N Y Acad Sci 1051:716-729
7. Ridderstad A, Abedi-Valugerdi M, Moller E (1991) Cytokines in rheumatoid arthritis. Ann Med 23(3):219-223
8. Miesel R, Murphy MP, Kroger H (1996) Enhanced mitochondrial radical production in patients which rheumatoid arthritis correlates with elevated levels of tumor necrosis factor alpha in plasma. Free Radic Res 25(2):161-169
9. Jaswal S, Mehta HC, Sood AK, Kaur J (2003) Antioxidant status in rheumatoid arthritis and role of antioxidant therapy. Clin Chim Acta 338(1-2):123-129
10. Jira W, Spiteller G, Richter A (1997) Increased levels of lipid oxidation products in low density lipoproteins of patients suffering from rheumatoid arthritis. Chem Phys Lipids 87(1):81-89
11. Frears ER, Zhang Z, Blake DR, O'Connell JP, Wiynard PG (1996) Inactivation of tissue inhibitor of metalloproteinase-1 by peroxynitrite. FEBS Lett 381(1-2):21-24
12. Ozturk HS, Cimen MY, Cimen OB, Kacmaz M, Durak I (1999) Oxidant/ antioxidant status of plasma samples from patients with rheumatoid arthritis. Rheumatol Int 19:35-37
13. McKeown MJ, Hall ND, Corvalan JR (1984) Defective monocyte accessory function due to surface sulphydryl (SH) oxidation in rheumatoid arthritis. Clin Exp Immunol 56(3):607-613
14. Banford JC, Brown DH, Hazelton RA, McNeil CJ, Smith WE, Stturrock RD (1982) Altered thiol status in patients with rheumatoid arthritis. Rheumatol Int 2(3):107-111
15. Goldstein IM, Kaplan HB, Edelson HS, Weissmann G (1979) Ceruloplasmin. A scavenger of superoxide anion radicals. J Biol Chem 254(10):4040-4045
16. Rafter GW (1994) Plasma thiols, copper and rheumatoid arthritis. Med Hypotheses 43(1):59-61
17. Kiziltunc A, Cogagil S, Cerrahoglu L (1998) Carnitine and antioxidants levels in patients with rheumatoid arthritis. Scand J Rheumatol 27(6):441-445
18. Dogan P, Tanrikulu G, Soyuer U, Kose K (1994) Oxidative enzymes of polymorphonuclear leucocytes and plasma fibrinogen, ceruloplasmin, and copper levels in Behcet's disease. Clin Biochem 27(5):413-418
19. Gutteridge JM, Winyard PG, Blake DR, Lunec J, Brailsford S, Halliwell B (1985) The behaviour of caeruloplasmin in stored human extracellular fluids in relation to ferroxidase II activity, lipid peroxidation and phenanthroline-detectable copper. Biochem J 230(2):517-523
20. Mackness B, Durrington PN, Mackness MI (1998) Human serum paraoxonase. Gen Pharmacol 31(3):329-336
21. Durrington PN, Mackness B, Mackness MI (2001) Paraoxonase and atherosclerosis. Arterioscler Thromb Vasc Biol 21(4):473-480
22. Mackness MI, Mackness B, Durrington PN (2003) Paraoxonase and coronary heart disease. Atheroscler Suppl 3(4):49-55
23. Arnet FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31(3):315-324
24. Ellman GL (1959) Tissue sulfhydryl groups. Arch Biochem Biophys 82:70-77
25. Hu ML, Louie S, Cross CE, Motchnik P, Halliwell B (1993) Antioxidant protection against hypochlorous acid in human plasma. J Lab Clin Med 121(2):257-262
26. La Du BN, Eckerson HW (1984) The polymorphic paraoxonase/arylesterase isozymes of human serum. Fed Proc 43:2338-2341
27. Sunderman FW, Nomoto S (1970) Measurement of human serum ceruloplasmin by its p-phenylenediamine oxidase activity. Clin Chem 16(11):903-910
28. Erel O (1998) Automated measurement of serum ferroxidase activity. Clin Chem 44(11):2313-2319
29. Gorog P, Kotak DC, Kovacs IB (1991) Simple and specific test for measuring lipid peroxides in plasma. J Clin Pathol 44(9):765-767
30. Pinals RS, Masi AT, Larsen RA (1981) Preliminary criteria for clinical remission in rheumatoid arthritis. Arthritis Rheum 24(10):1308-1315
31. Symmons DP, Jones MA, Scott DL, Prior P (1998) Longterm mortality outcome in patients with rheumatoid arthritis: Early presenters continue to do well. J Rheumatol 25:1072-1077
32. Van Doornum S, McColl G, Wicks IP (2002) Accelerated atherosclerosis: An extraarticular feature of rheumatoid arthritis? Arthritis Rheum 46(4):862-873
33. Gutteridge JM (1985) Inhibition of the Fenton reaction by the protein caeruloplasmin and other copper complexes. Assessment of ferroxidase and radical scavenging activities. Chem Biol Interact 56(1):113-120
34. Louro MO, Cocho JA, Mera A, Tutor JV (2000) Immunochemical and enzymatic study of ceruloplasmin in rheumatoid arthritis. J Trace Elem Med Biol 14(3):174-178
35. Gambhir JK, Lali P, Jain AK (1997) Correlation between blood antioxidant levels and lipid peroxidation in rheumatoid arthritis. Clin Biochem 30(4):351-355
36. Hall ND, Maslen CL, Blake DR (1984) The oxidation of serum sulph-hydryl groups by hydrogen peroxide secreted by stimulated phagocytic cells in rheumatoid arthritis. Rheumatol Int 4(1):35-38
37. Hall ND, Blake DR, Bacon PA (1982) Serum sulphydryl levels in early synovitis. J Rheumatol 9(4):593-596
38. Giustarini D, Lorenzini S, Rossi R, Chindamo D, Di Simplicio P, Marcolongo R (2005) Altered thiol pattern in plasma of subjects affected by rheumatoid arthritis. Clin Exp Rheumatol 23(2):205-212
39. Shih DM, Gu L, Xia YR, Navab M, Li WF, Hama S et al (1998) Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 394(6690):284-287
40. Tanimoto N, Kumon Y, Suehiro T, Ohkubo S, Ikeda Y, Nishiya K et al (2003) Serum paraoxonase activity decreases in rheumatoid arthritis. Life Sci 72(25):2877-2885
41. Baskol G, Demir H, Baskol M, Kilic E, Ates F, Kocer D et al (2005) Assessment of paraoxonase 1 activity and malondialdehyde levels in patients with rheumatoid arthritis. Clin Biochem 38(10):951-955
42. Maury CP, Junge W, Teppo AM (1984) Serum esterase activity in reactive systemic amyloidosis and its relation to amyloid A degrading activity. J Lab Clin Med 104(5):761-766
43. Feingold KR, Menon RA, Moser AH, Grunfeld C (1998) Paraoxonase activity in the serum and hepatic mRNA levels decrease during the acute phase response. Atherosclerosis 139(2):307-315
44. Kumon Y, Nakauchi Y, Suehiro T, Shiinoki T, Tanimoto N, Inoue M et al (2002) Proinflammatory cytokines but not acute phase serum amyloid A or C-reactive protein, downregulate paraoxonase 1 (PON1) expression by HepG2 cells. Amyloid 9(3):160-164
45. Aviram M, Billecke S, Sorenson R, Bisgaier C, Newton R, Rosenblat M et al (1998) Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different from that required for its arylesterase/paraoxonase activities: Selective action of human paraoxonase allozymes Q and R. Arterioscler Thromb Vasc Biol 18(10):1617-1624
46. Aviram M, Rosenblat M, Billecke S, Erogul J, Sorenson R, Bisgaier CL et al (1999) Human serum paraoxonase (PON 1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants. Free Radic Biol Med 26:892-904